168 related articles for article (PubMed ID: 20160054)
21. [Mechanisms of the action of drugs in the short-course chemotherapy].
Mitchison DA
Bull Int Union Tuberc; 1985; 60(1-2):36-40. PubMed ID: 2416374
[No Abstract] [Full Text] [Related]
22. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.
Ji B; Chauffour A; Andries K; Jarlier V
Antimicrob Agents Chemother; 2006 Apr; 50(4):1558-60. PubMed ID: 16569884
[TBL] [Abstract][Full Text] [Related]
23. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
[TBL] [Abstract][Full Text] [Related]
24. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results.
Valerio G; Bracciale P; Manisco V; Quitadamo M; Legari G; Bellanova S
J Chemother; 2003 Feb; 15(1):66-70. PubMed ID: 12678417
[TBL] [Abstract][Full Text] [Related]
25. [Optimization of tuberculosis complex chemotherapy with the use of moxifloxacin].
Perel'man MI; Cokolova GB; Mozhokina GN; Lazareva IaV; Strekchev AIu; Elistratova NA
Antibiot Khimioter; 2004; 49(6):20-4. PubMed ID: 15628798
[TBL] [Abstract][Full Text] [Related]
26. Protein binding investigation of first-line and second-line antituberculosis drugs.
Fage D; Aalhoul F; Cotton F
Int J Antimicrob Agents; 2023 Dec; 62(6):106999. PubMed ID: 37838149
[TBL] [Abstract][Full Text] [Related]
27. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
Gillespie SH; Gosling RD; Uiso L; Sam NE; Kanduma EG; McHugh TD
J Antimicrob Chemother; 2005 Dec; 56(6):1169-71. PubMed ID: 16223939
[TBL] [Abstract][Full Text] [Related]
28. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
[TBL] [Abstract][Full Text] [Related]
30. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
31. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
Burman WJ; Goldberg S; Johnson JL; Muzanye G; Engle M; Mosher AW; Choudhri S; Daley CL; Munsiff SS; Zhao Z; Vernon A; Chaisson RE
Am J Respir Crit Care Med; 2006 Aug; 174(3):331-8. PubMed ID: 16675781
[TBL] [Abstract][Full Text] [Related]
32. [Antimicrobial resistance in tuberculosis].
Gutiérrez-Aroca JB; Ruiz P; Casal M
Rev Esp Quimioter; 2013 Dec; 26(4):332-6. PubMed ID: 24399346
[TBL] [Abstract][Full Text] [Related]
33. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
[TBL] [Abstract][Full Text] [Related]
34. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
Lanoix JP; Betoudji F; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
[TBL] [Abstract][Full Text] [Related]
35. Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication.
Lee WY; Ling M; Anderson G; Achawal S; Thaker HK
J Med Microbiol; 2011 Oct; 60(Pt 10):1550-1552. PubMed ID: 21659503
[TBL] [Abstract][Full Text] [Related]
36. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.
Dickinson JM; Aber VR; Mitchison DA
Am Rev Respir Dis; 1977 Oct; 116(4):627-35. PubMed ID: 411404
[TBL] [Abstract][Full Text] [Related]
37. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
38. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.
Xu J; Lu Y; Fu L; Zhu H; Wang B; Mdluli K; Upton AM; Jin H; Zheng M; Zhao W; Li P
Int J Tuberc Lung Dis; 2012 Aug; 16(8):1119-25. PubMed ID: 22691726
[TBL] [Abstract][Full Text] [Related]
40. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
Nuermberger EL; Yoshimatsu T; Tyagi S; O'Brien RJ; Vernon AN; Chaisson RE; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2004 Feb; 169(3):421-6. PubMed ID: 14578218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
